undamentalytics Newsletter
Sign in

Scilex Holding Co revenue

Scilex Holding Co's revenue was $30.3m in fiscal 2025, down 46.5% on the year before. Since fiscal 2020 ($23.6m) it has grown at a compound 5.1% a year. Over the last twelve months it was $31.6m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue24313847573032
Growth on the year before—+32.9%+21.4%+22.9%+21.1%−46.5%—
Gross profit2128273116712618
Gross margin90.9%88.4%71.6%66.5%——55.5%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Scilex Holding Co $31.6m -28.5% -12.0%
Verrica Pharmaceuticals Inc. $30.3m 106.2% 52.2%
Sunshine Biopharma Inc. $35.3m -2.7% 34.5%
Jaguar Health, Inc. $27.8m 135.5% 76.5%
BGM Group Ltd. $37.9m 51.1% —
IM Cannabis Corp. $39.2m -0.7% —

Compare with peers

Head to head: SCLX vs VRCASBFM vs SCLXJAGX vs SCLX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Scilex Holding Co's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Scilex Holding Co.